Abstract
You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) III1 Apr 2017MP53-04 COMPARISON OF THE LENGTH OF TIME FROM INITIATION OF ANDROGEN DEPRIVATION THERAPY TO SALVAGE CHEMOTHERAPY IN AFRICAN AMERICAN MALES AND CAUCASIAN MALES WITH CASTRATE RESISTANT PROSTATE CANCER Maria Uloko, Yunhua Fan, Stephanie Jarosek, and Barinath Konety Maria UlokoMaria Uloko More articles by this author , Yunhua FanYunhua Fan More articles by this author , Stephanie JarosekStephanie Jarosek More articles by this author , and Barinath KonetyBarinath Konety More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.1655AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Studies have shown that systemic chemotherapy can improve survival in patient who develop castration resistant prostate cancer. We evaluate the time to chemotherapy from initiation of ADT by racial subgroups in men with prostate cancer. METHODS We identified 81,579 men diagnosed with prostate cancer between 2004-2009 from the Surveillance, Epidemiology and End Results database (SEER). We then risk stratified the men based on the DAmico criteria. Those with one or more unknown tumor variables (prostate specific antigen, T stage and/or Gleason Score) were labeled unknown. Of this group, we identified 2370 men who received chemotherapy after ADT, 2137 non-Hispanic Caucasian and non-Hispanic 233 African American. Overall and risk-stratified analyses were performed using T-test and multiple linear regression which compared the time interval from diagnosis to chemotherapy and from initiation of ADT to initiation of chemotherapy in African Americans vs. Caucasians. RESULTS The median time from diagnosis to chemotherapy was 32 months and from initiation of ADT to chemotherapy was 25 months. The median time from ADT to chemotherapy for the low risk group was 16 months (n= 119), intermediate risk was 29 months (n = 313), high risk 29 months (n = 920) and unknown 21 months (n = 1018). African American males had a median length of 18 months compared to Caucasian males 25 months (p value from t-test = 0.006). After adjusting for age, year of diagnosis, income, education, Charlson comorbidity score, and risk of prostate cancer, the difference is still significant: the least squares mean time from ADT to chemo is 22.5 months in AA vs. 27.5 months in CA (p=0.006). CONCLUSIONS The length of time from ADT to salvage chemotherapy in African American males is shorter compared to Caucasian males. This may suggest that AA men have cancers that progress faster on ADT compared to prostate cancer in Caucasian men. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e714 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Maria Uloko More articles by this author Yunhua Fan More articles by this author Stephanie Jarosek More articles by this author Barinath Konety More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call